On March 6, 2026, Day One Biopharmaceuticals, Inc. entered into a merger agreement with Servier Pharmaceuticals, proposing a cash tender offer at $21.50 per share, subject to certain conditions. This merger will make Day One a wholly owned subsidiary of Servier after the successful completion of the offer.